Director, GLP Quality Assurance

Director, GLP Quality Assurance

Redwood City, California, United States

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

The Associate Director (AD) Good Laboratory Practice Quality Assurance (GLP QA) is responsible for ensuring Good Laboratory Practices (GLP) compliance at RevMed and external vendors contracted to perform regulated work on behalf of RevMed including all GLP vendors.

The AD GLP QA responsibilities include for research laboratory vendors that perform work to support regulated clinical studies.

The AD GLP QA develops the annual vendor audit plan.

The AD GLP QA performs and/or manages vendor audits including:

• Development of the audit plan, audit conduct, and reporting
• Tracking and coordination of audit closure tasks including review of observation responses from vendor(s) in conjunction with operational subject matter experts (SMEs), as applicable.
• Provision of vendor approval recommendations
• Maintenance of vendor approval status in Veeva.

The AD GLP QA performs or participates in internal audits.

The AD GLP QA provides QA review of CRO study protocols and reports for compliance utilizing a risk-based approach, as needed and serves as an advisor to the Nonclinical Development and Clinical Pharmacology (NDCP) to resolve compliance issues.

The AD GLP QA monitors vendor QA units for compliance with applicable regulations including review of vendor study specific QA audit reports.

The AD GLP QA advises Sponsor(s) on compliance requirements for test and control article used in GLP studies.

The AD GLP QA liaises and/or consults with GLP vendor QA departments on study-related issues such as deviations, investigations, CAPAs and other compliance issues.

The AD GLP QA provides annual GLP training or liaises with an external trainer to provide GLP training to RevMed functional team(s).

The AD GLP QA attends functional area meetings (e.g., NDCP and Biomarker group) to discuss and review new or on-going issues, projects, and/or studies.

The AD GLP QA works with QA management for resource planning, as needed.

The AD GLP QA attends periodic clinical QA group meetings, as needed.

The AD GLP QA provides periodic quality and compliance updates to QA management.

The AD GLP QA develops/prepares standard operating procedure (SOPs) content to GLP audits, and reviews functional area and QA SOPs for GLP compliance.

The AD GLP QA provides consultative QA guidance for computerized system vendors (and systems) supporting GLP studies.

Required Skills, Experience and Education:

• Bachelor's or Master's Degree.
• 12+ years of experience in global Good Laboratory Practice (GLP) Quality Assurance (QA).
• Extensive audit and inspection management experience.

Preferred Skills:

• Registered Quality Assurance Professional – Good Laboratory Practice (RQAP-GLP).
• Planning and scheduling expertise.
• Experienced in effective prioritization of competing initiatives and tasks across multiple projects.
• Ability to communicate effectively with senior leadership, management and cross functional teams.
• Ability to manage workstreams to maintain delivery timelines through disciplined planning, tracking and follow-up.
• Ability to balance detail-oriented execution with strategic oversight.
• Experienced with the proactive identification, assessment and mitigation of risks and with timely issue escalation, as applicable.
• Regulatory expertise with at least the following regulations and guidance:
• 21CFR Part 58 Good Laboratory Practice
• 21 CFR Part 11 Electronic Records; Electronic Signatures
• OECD #1 – 24 Standards and Advisory Documents on Good Laboratory Practices
• ICH E6 (R2 and R3) Good Clinical Practices
• Japanese Ministry of Health Labor and Welfare (MHLW) – Good Laboratory Practice
• Applicable US and EU guidance documents including bioanalytical, in vitro and in vivo genetic, Phototox, and hERG toxicology studies
• Experience with the following audit types.
• Testing facilities.
• Bioanalytical and PK data analysis Labs.
• hERG and Phototoxicity testing facilities.
• Archives – biorepositories, paper and electronic data storage.
• Computer Systems Validation.
• Biomarker Labs (including Artificial Intelligence and Machine Learning).
• Central Laboratories.